RT Journal Article
SR Electronic
T1 Association between prescription drugs and all-cause mortality risk in the UK population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.08.24303967
DO 10.1101/2024.03.08.24303967
A1 Morin, Jonas
A1 Rolland, Yves
A1 Bischoff-Ferrari, Heike A.
A1 Ocampo, Alejandro
A1 Perez, Kevin
YR 2024
UL http://medrxiv.org/content/early/2024/03/10/2024.03.08.24303967.abstract
AB Although most drugs currently approved are meant to treat specific diseases or symptoms, it has been hypothesized that some might bear a beneficial effect on lifespan in healthy older individuals, outside of their specific disease indication. Such drugs include, among others, metformin, SGLT2 inhibitors and rapamycin. The UK biobank has recorded prescription medication and mortality data for over 500’000 patients during more than 40 years. In this work we examined the impact of the top 406 prescribed medications on overall mortality rates within the general population of the UK. As expected, most drugs harbor a negative effect on lifespan, probably due to the underlying negative effect of the disease the drug is intended for. Importantly, a few drugs seem to have a beneficial effect on lifespan, including notably Sildenafil, Atorvastatin, Naproxen and Estradiol. These retrospective results warrant further investigation in randomized controlled trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. The data access and analyses in this study were funded by EPITERNA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval UK Biobank has obtained ethics approval from the Northwest Multi-Centre Research Ethics Committee (approval number: 11/NW/0382) and has obtained informed consent from all participants. Data access Data access was granted as "Approved Research" study from the UK biobank, principal investigator: Dr Kevin Perez (EPITERNA SA), Approved Research ID: 107065, Approval date: August 17th, 2023. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript. No additional data available.